AI
SWTX

Atom Investors’s SpringWorks Therapeutics SWTX Stock Holding History

Atom Investors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,398
Closed -$1.5M – 329
2021
Q1 		$1.5M Sell
20,398
-23,681
-54% -$1.85M 0.25% 91
2020
Q4 		$3.2M Buy
44,079
+38,223
+653% +$2.46M 0.32% 84
2020
Q3 		$279K Buy
+5,856
New +$249K 0.03% 308

Other funds holding SWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Atom Investors's SWTX Position: Q2 2021 in Review

Atom Investors sold out of SpringWorks Therapeutics (SWTX) in Q2 2021, closing a stake of 20,398 shares — an estimated $1.5M sold.

Atom Investors first reported a position in SWTX in Q3 2020 and held it in 3 quarters. The position peaked at $3.2M in Q4 2020. 135 funds tracked by Wall St. Rank hold SWTX as of Q2 2021.

  • Atom Investors reported no remaining SpringWorks Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Atom Investors sold 20,398 SpringWorks Therapeutics shares in Q2 2021, an estimated $1.5M.
  • Atom Investors first reported a position in SpringWorks Therapeutics in Q3 2020 and held it in 3 quarters.
  • Atom Investors's SpringWorks Therapeutics position peaked at $3.2M in Q4 2020.
  • 135 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2021.

Based on Atom Investors's 13F filing for Q2 2021, filed 16 Aug 2021.